Navigation Links
BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
Date:5/8/2008

BIRMINGHAM, Ala., May 8 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced financial results for the quarter ended March 31, 2008. The Company reported revenues of $10.8M in the first quarter of 2008, compared to $9.2M in the first quarter of 2007. The net loss for the quarter ended March 31, 2008 was $13.1M, or $0.34 per share, compared to a net loss for the quarter ended March 31, 2007 of $8.8M, or $0.30 per share.

Research and development (R&D) expenses were $21.9M in the first quarter of 2008, compared to R&D expenses of $16.2M in the first quarter of 2007. The increase is primarily attributable to costs associated with the advancement of clinical programs, the costs related to manufacturing lead drug candidates and the increase in personnel related costs, which included an increase in the non-cash share-based compensation charge.

General and administrative (G&A) expenses for the first quarter of 2008 were $2.9M compared to G&A expenses of $2.4M for the same quarter in 2007. The higher G&A expenses were primarily due to an increase in professional fees and personnel related costs.

As of March 31, 2008, the Company had cash, cash equivalents and investments of $81.2 million.

"Our financial flexibility and stability will allow us to pursue all of the significant milestones we have set forth for our pipeline candidates," said Jon P. Stonehouse, Chief Executive Officer of BioCryst. "2008 will be a very active year in the clinic for BioCryst, and we are fortunate to have the financial basis to advance our drug candidates in order to deliver the greatest value to both patients and our shareholders."

Recent Corporate Highlights

Forodesine HCl cutaneous T-cell lymp
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
2. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
3. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
4. BioCryst to Present at UBS 2007 Global Life Sciences Conference
5. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
6. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
7. Dendreon Reports First Quarter 2008 Financial Results
8. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
9. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
10. Oncothyreon Reports First Quarter 2008 Financial Results
11. iCAD Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... phones to cars and flashlights, batteries play an ... companies constantly are seeking ways to improve battery ... using a water-based solution, researchers at the University ... efficient nuclear battery that could be used for ... in automobiles and also in complicated applications such ...
(Date:9/16/2014)... Cardioxyl Pharmaceuticals, Inc. announced today ... to be effective in animal models following oral (capsule) ... infusions that could pave the way for convenient outpatient ... at the Heart Failure Society of America,s (HFSA) 18 ... Vegas . The research, conducted in ...
(Date:9/16/2014)... Sept. 16, 2014  The Council for Entrepreneurial ... organization in the country, today released a mid-year ... It showed that in the ... startups in the technology, life science, ... investment from a variety of sources. Significant investment in ...
(Date:9/16/2014)... Arizona (PRWEB) September 16, 2014 ... develops safe and effective products to treat patients ... use of a proprietary SPACEā„¢ Technology Platform announced ... and President will present at the White Hat ... at the Hyatt Regency Phoenix. In addition, ...
Breaking Biology Technology:Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3
... , June 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ... been granted its 35th U.S. Patent, # 7,731,951 entitled "Viruses for ... for treating cell proliferative disorders by administering modified vaccinia virus to ... , , ...
... June 17 ChemoCentryx, Inc., today announced that ... drug candidate CCX354 at the Annual European Congress of ... drug candidate designed to specifically target the CCR1 chemokine ... (RA).  Data demonstrating that CCX354 was safe and well ...
... Researchers at Rensselaer Polytechnic Institute have developed a ... that measure only billionths of a meter thick. ... works on nearly any surface including silicon wafers, ... manufacturing. Sang-Kee Eah, assistant professor in the ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces Issuance of 35th U.S. Patent 2ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR) 2ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR) 3ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR) 4Researchers develop ultra-simple method for creating nanoscale gold coatings 2
(Date:9/17/2014)... their environmental impact recently scored a major win. In ... the bags, and Governor Jerry Brown is expected to ... yielding without a fight, according to an article in ... of the American Chemical Society. , Alexander Tullo, a ... logged its first small victory in 1990 when Nantucket ...
(Date:9/17/2014)... Evolution and Yale University offers compelling support for the ... partially predict the likelihood of being diagnosed with mental ... life. The study analyzed medical records of 1.75 million ... 30 years, and adjusted for almost all other known ... Proceedings of the Royal Society, London B . ...
(Date:9/17/2014)... in Biomedical Informatics at IMIM (Hospital del Mar Medical ... (UPC) have recently published a study in eLife ... important role in the evolution of new proteins, some ... be discovered., Ribosomes produce proteins from the instructions found ... human genome is RNA containing information for the synthesis ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Parts of genome without a known function may play a key role in the birth of new proteins 2
... mountain meadows in the Pacific Northwest are declining rapidly due ... growing seasons and other factors allow trees to invade these ... wildflowers. The process appears to have been going on ... Jefferson Park, a subalpine meadow complex in the central Oregon ...
... Planck Institute for Chemical Energy Conversion (MPI CEC) and ... on a hydrogen-producing enzyme that the environment of the ... enzyme. Thus, it can very efficiently produce hydrogen, which ... research team describes their results in the journal " ...
... Calif.During the early developmental stages of vertebratesanimals that ... undergo extensive rearrangements, and some cells migrate over ... novel roles as differentiated cell types. Understanding how ... an embryo is an important and complex goal ...
Cached Biology News:Mountain meadows dwindling in the Pacific Northwest 2Temporary storage for electrons: Natural method of producing hydrogen 2Developmental bait and switch 2Developmental bait and switch 3
Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...
SHEEP ANTI HUMAN CATHEPSIN G...
Request Info...
RABBIT ANTI TRANSFERRIN RECEPTOR...
Biology Products: